ArticleBMC urology2025
Beyond diagnosis: exploring the extended clinical utility of urine fluorescence in situ hybridization in upper tract urothelial carcinoma.
Article in BMC urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundWhile urine fluorescence in situ hybridization (FISH) has established itself as a crucial diagnostic modality for upper tract urothelial carcinoma (UTUC), the broader clinical applications of this technique are yet to be fully elucidated.
methodsThis retrospective cohort study analyzed patients who underwent urine FISH test at Qilu Hospital of Shandong University from 2022 to 2025. We assessed its clinical value by constructing ROC curves. Additionally, a novel predictive tool based on urine FISH features and blood routine examination indicators was then developed to enhance urine FISH’s staging predictive ability. We also explored the correlation of urine FISH features with LVI, Ki67, and HER2.
resultsThe study encompassed 220 patients, revealing the utility of urine FISH test in informing clinical treatment. Particularly, among the urine FISH features evaluated, CEP7 demonstrated superior performance in identifying patients requiring radical nephroureterectomy (AUC = 0.885), distinguishing renal pelvis carcinoma (AUC = 0.926), and discriminating non-UTUC individuals (AUC = 0.911). Regrettably, urine FISH features demonstrated constrained predictive efficacy in UTUC staging. Consequently, leveraging machine learning, we developed a staging prediction tool based on urine FISH features and blood routine examination indicators, with the SVM model demonstrating optimal predictive performance. In addition, we observed that certain urine FISH features were associated with the expression levels of HER2 and Ki67 in neoplastic tissues.
conclusionsOur study provides an initial exploration into the extended utility of urine FISH beyond conventional diagnostics in UTUC, thereby offering novel insights for the advancement of precision oncology in this disease. CLINICAL TRIAL NUMBER: Not applicable. RETROSPECTIVELY REGISTERED: KYLL-202412-044.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.